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Abstract The present study demonstrates capacity of α-
MSH to augment recovery from ischemia/reperfusion (I/R)
-induced retinal damage in vivo and correlation of its pro-
tective effects with expression of heme oxygenase-1 (HO-
1). Used techniques include ocular ischemia and reperfu-
sion, electroretinography, histology, electron microscopy,
and molecular-biological techniques. The results demon-
strate the α-MSH-mediated inhibition of I/R-induced func-
tional deterioration of the retina. Outcomes suggest that the
protective effects of α-MSH occur mainly through HO-1-
dependent pathways but HO-1-independent mechanisms
may also contribute to protection. The observation that
post-ischemic treatment with α-MSH exhibits therapeutic
efficacy in the same range as pre-ischemic treatment, is a
novel result. This outcome suggests a highly conserved
protective role for α-MSH as a major stress response mech-
anism—and offers the possibility for development of novel
therapeutic strategies utilizing this hormone, in particular in
treatment of conditions resulting from I/R injury, such as
deterioration of retinal microcirculation. The merit of the
study lies in the fact that I/R injury contribute significantly
to the severity of retinopathies. However, currently there are
no evidence-based treatments for retinal I/R injury available
for clinical use. Our finding suggests that α-MSH may have
a very wide range of uses in the prevention of I/R-mediated
pathologies.
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Abbreviations
α-MSH Alpha-melanocyte-stimulating hormone
ERG Electroretinography
HO-1 Heme oxygenase-1
I/R Ischemia/reperfusion; control baseline =
nonischemic vehicle-treated control
SnPP Sn-protoporphyrin IX
Introduction
Ischemia/reperfusion (I/R) injury and the resulting deterio-
ration of tissue microcirculatory capacity are major contrib-
uting factors in many diseases, including retinal vascular
occlusion (Jonas et al. 2010), glaucoma (Agarwal et al.
2009), and diabetic retinopathy (Curtis et al. 2009).
Despite an evolving understanding of I/R-associated disease
pathogenesis, no evidence-based strategies for the preven-
tion and therapy of I/R-related ocular diseases are available
at the time of this writing. The results of previous work by
the authors of this report suggest that alpha-melanocyte-
stimulating hormone (α-MSH) may have potential for the
prevention and treatment of I/R-associated pathologies, in-
cluding ocular disease (Vecsernyes et al. 2003).
This tridecapeptid homone is derived from posttranslational
processing of a precursor protein called proopiomelanocortin.
Physiological functions of melanocyte-stimulating hormones
include: stimulation of melanogenesis (Tsatmali et al. 2002),
regulation of appetite and energy balance (Morton et al. 2006),
sexual arousal, and erectile function (Shadiack et al. 2007),
along with a wide range of anti-inflammatory and protective
effects, most notably protection from I/R injury (Lipton et al.
1994).α-MSH is known to protect against ischemic damage of
the brain (Forslin Aronsson et al. 2006), kidney (Chiao et al.
1997), and gastrointestinal tract (Zou et al. 2003). Additionally,
authors have demonstrated α-MSH-mediated preservation of
ischemic-reperfused myocardium (Bazzani et al. 2001;
Vecsernyes et al. 2003). Ocular I/R pathologies typically cause
significantly adverse effects on retinal tissue as well. However,
at the time of this writing, the ability of α-MSH to protect the
retina has not been comprehensively investigated.
Heme oxygenase 1 (HO-1), also known as heat shock
protein 32, has been shown to mitigate the effects of many
human diseases by contributing to the regulation of inflamma-
tory processes and restoration of normal immune homeostatic
conditions (Csonka et al. 1999; Juhasz et al. 2011; Haines et al.
2012). The enzyme has also been reported to play a critical
role in α-MSH protection against I/R injury in skin (Kokot et
al. 2009), gut (Zou et al. 2003), and peritoneal macrophages
(Lam et al. 2005). The present investigation evaluates a cor-
relation between HO-1 expression and α-MSH amelioration
of I/R injury to the retina. The outcomes reported here are the
first demonstrations of α-MSH-mediated recovery from I/R-
induced retinal damage.
Study Goals
The present study demonstrates the protective effects of α-
MSH on the recovery of I/R-induced retinal damage in a rat
model. A major goal of this research was to identify an
effective α-MSH dose range to achieve significant preventive
and therapeutic effects in the test animals. These evaluations
were conducted using electroretinography (ERG), as de-
scribed below. Following the identification of an optimal dose
range for the outcomes measured, assessments of related
physiological parameters were investigated, including α-
MSH effects on the degree of I/R-induced retinal edema,
structural degenerative changes on the retina, and HO-1 pro-
tein expression. Results shown here demonstrate a correlation
between α-MSH, therapeutic outcomes, and HO-1 expres-
sion. A corollary objective of the present study was to suggest
whether non-HO-1-dependent mechanisms downstream of α-
MSH might also contribute to protective effects of the hor-
mone. Finally, a hypothesis that α-MSH is an evolutionarily
conserved stress response hormone was evaluated by studying
the effect of post-ischemic treatment with α-MSH.
Materials and Methods
Animals
The experiments described in the present report were
conducted using male Sprague Dawley rats (Crl/SD).
Animals weighing 300–350 g were purchased from
Charles River Laboratories International, Inc. (Wilmington,
Massachusetts). All animals received humane care in com-
pliance with the ARVO Statement for the Use of Animals in
Ophtalmic and Vision Research and the NIH guidelines. All
of the protocols used in the present study were approved by
the Institutional Animal Care Committee of University of
Debrecen in Debrecen, Hungary. The rats were fed regular
rodent chow ad libitum with free access to water until the
initiation of experimental procedures.
Ocular I/R
The animals were anaesthetized with intramuscular injections
of ketamin/xylazine (50/5 mg/kg) at the outset of each exper-
imental procedure. Subsequently, the retinal artery supplying
blood to left eye of each animal was surgically occluded using
a protocol previously applied by the authors of related studies
(Szabo et al. 2004). Briefly, eyelids were retracted using
sutures, followed by the use of a traction-type occluder (a silk
suture thread through a polyethylene guide cannula) for retinal
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artery blockage. The suture was placed behind the eyeball,
loosely around the optic nerve, central retinal artery, ciliary
arteries, and the retrobulbar connective tissue. By pulling the
suture and pressing the tube against the surface of the optic
nerve, ischemia was induced and maintained for the required
length of time. Ischemia was verified macroscopically with a
120-D lens. Reperfusion of retinal tissue was accomplished by
post-ischemic release of the occluder, allowing resumption of
blood flow through the retinal artery.
Electroretinography
The animals were prepared for electroretinographic measure-
ments by anesthesia with 50/5 mg/kg of ketamin/xylazine,
administered as intramuscular injections. Both pupils of each
animal were dilated with 0.5 % cyclopentolate hydrochloride
(Humapent, Teva, Hungary) and 10 % phenylephrine hydro-
chloride (Neosynephrin-HCL, Ursapharm, Saarbruecken,
Germany).
Detailed description of the system used by our workgroup
for recording electroretinograms is as follows. Five silver
needle electrodes were used for each measurement. In clinical
practice ERG is praised for being a noninvasive technique,
however, in our case, where eyes of the animals are used as
experimental samples for different molecular biological as-
sessments, this was not a requirement. And we found that in
contrast to regular contact lens type electrodes, electrical
contact, and signal throughput of needle electrodes carefully
and superficially inserted into corneal surface, is much better.
Retinal signals were analyzed using two measuring electrodes
(one on each eye), inserted into corneal surfaces so as to avoid
scleral damage or corneal perforation. Two reference elec-
trodes were positioned on the earlobes of each animal (one
on each earlobe) and the main ground electrode at the glabella.
Effective electrical contacts and protection of eyes from de-
hydration was provided by a solution of methylcellulose (0.
5 %). After a short dark adaptation period (20 min), the eyes
were illuminated with a self-built stroboscope (20 cd/m2, 0.
5 Hz). Electrical signals corresponding to retinal changes
passed through an ERG-recording system (ADInstruments,
Australia) composed of an amplifier and an analog–digital
converter (Bridge Amp and PowerLab, ADInstruments,
Australia), displayed on a PC monitor, and analyzed using a
software, PowerLab Chart (Version 5.2.2., ADInstruments,
Australia). Obtained electroretinograms contain well identifi-
able, definite spikes composed of a negative peak followed by
a highly positive peak which then fade out through another
negative peak, and a steady, moderate extraneous signal
(background noise). Although the appearance is not the same
as with other “standard” ERG-systems, the highly positive
peak is definitely the maximum of b wave, preceded by a
negative peak (the negative maximum of a wave). This con-
clusion can be drawn from the fact that these electrical
activities (spikes) occur consistently after light stimulus with
the same rhythm, same frequency the stroboscope has (0.
5 Hz), and that the most intense electrical activity on a com-
mon, “standard” ERG recording to cause such highly positive
peak is the b wave alone. However, a waves or other minor
components of the ERG cannot be clearly identified: e.g.,
amplitude of the probable a waves was in the same range as
extraneous signal (background noise) present in each of the
recordings, which hinders clear interpretation of a wave ERG
data. Nevertheless, it should also be mentioned that in this
study there was no need to be able to measure such subtleties
as c waves or oscillatory potencials, only changes in electrical
activity of retina, which is related to retina function. Actual
amplitudes of b waves were measured between the
(preceding) negative and the highly positive peaks of a spike.
The outcome of ERG experiments formerly conducted by the
authors with the same recording system demonstrated that the
aforementioned experimental strategy provides reproducible,
cost-effective data on retinal function, closely correlated to the
survival of retinal cells (Varga et al. 2011).
Processing for Examination by Light and Electron
Microscopy
Samples designated for examination by light or fluorescent
microscopy were produced according to the following gen-
eral protocol: the fixation of retinal tissue was accomplished
via trans-aortic cardiac cannulization, accompanied by a
surgical incision in the right ventricle to allow a free outflow
of blood. The vasculature of each animal was flushed
(perfused) with physiological saline (0.9 % NaCl) to clear
their system of blood. In each case, perfusion time was
limited to 20-s interval to minimize nervous tissue edema.
Physiological saline rinses were conducted concurrently
with the fixation of retinas with 100 ml Bouin solution,
followed by an extraction of bulbi and coronalis sectioning,
bisecting each eyeball along the ora serrata. The vitreum of
each eye was removed, and the bulbs were fixed, alcohol
dehydrated, and paraffinized.
Some paraffinized bulbi were processed into 7-μm sag-
ittal sections, which were then dyed with hematoxylin–eosin
(HE) and examined by light microscopy. According to pre-
vious reports, I/R-induced edema formation is well recog-
nized and documented in the inner plexiform layer of the
retina (Shakib and Ashton 1966; Juarez et al. 1986). The
average thickness for each eye was measured in the inner
plexiform layer in sagittal sections at near the optic disc and
expressed in micrometers using a manual scale on each glass
slide.
Paraffinized bulbi from a second group of eyes were sec-
tioned into 60-μm sagittal slices and prepared for electron
microscopic (EM) examination by fixation of tissue lipids
with osmium tetroxide (OsO4). (Fixation of tissue proteins
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was done earlier by the formaldehyde constituent of the Bouin
solution.) Samples fixed with OsO4 were alcohol
dehydrated and embedded into Araldite epoxy, and then
heat treated at 56 °C for 2 days to induce polymeriza-
tion (hardening). The samples were subsequently
processed by ultramicrotome into (ultrathin) sections
adequate for EM-based analysis.
Western Blot Analysis for HO-1 Protein Expression
Enucleated bulbi were suspended in a homogenisation buff-
er composed of Tris, 25 mM; NaCl, 25 mM; Na-
orthovanadate, 1 mM; NaF, 10 mM; Na-pyrophosphate,
10 mM; Okadaic acid, 10 nM; EDTA, 0.5 mM; PMSF,
1 mM; protease inhibitor cocktail; and distilled water
(Sigma-Aldrich, St. Louis, Missouri). Samples of homoge-
nized bulbi (50 μg protein per sample) and protein standards
were electrophoretically fractionated using SDS-
polyacrylamide gels with 12 % acrylamide-to-bis ratios.
Protein standards included PageRuler Prestained Protein
Ladder (Fermentas GmBH, Germany). Fractionized proteins
were subsequently transferred onto Protran Nitrocellulose
Membranes (Whatman International Ltd., UK) in a protocol
using Mini Trans-Blot Electrophoretic Transfer Cell (Bio-
Rad Laboratories Ltd.). Blocking of each blot was accom-
plished using Tris-buffered saline with Tween 20 for 1.5 h
with 5 % (w/v) nonfat dry milk. Subsequently each blot was
incubated overnight at 4 °C with primary anti-HO-1 anti-
bodies (Sigma-Aldrich), diluted 1:1,000 in TBS-T.
Subsequently, each blot was incubated for 1 h with horse-
radish peroxidase-conjugated secondary antibody, diluted
1:2,000 in TBS-T, and 5 % (w/v) nonfat dry milk. After
incubation and a short wash period, blots were treated
with enhanced chemiluminescence reagents (Millipore,
Billerica, MA). Detection was carried out via autoradi-
ography for varying lengths of time with Medical X-
Ray Film (Agfa-Gevaert N.V., Belgium). Films were
scanned and evaluated with Scion Image software
(Scion Corporation, Torrance, CA). GAPDH was used
as loading control (Sigma-Aldrich).
Measurement of Heme Oxygenase Activity
Activity of heme oxygenase (HO) in bulbal tissue was
measured according to the following general protocol:
enucleated bulbi were homogenized in a solution
containing HEPES, 10 mM; sucrose, 32 mM; DTT,
1 mM; EDTA, 0.1 mM; soybean trypsin inhibitor,
10 μg/ml; Leupeptin, 10 μg/ml; Aprotinin, 2 μg/ml;
pH 7.4 (homogentisate buffer). All reagents were pur-
chased from Sigma-Aldrich. The supernatant was col-
lected by centrifugation of the homogenate for 30 min
at 20,000×g at 4 °C. Assessment of HO activity was
performed on each sample of supernatant, according to
procedures used by Tenhunen et al. (1968). Briefly, HO
activity was estimated based on a spectrophotometric
measurement of bilirubin formation in a reaction mix-
ture containing: an aliquot of the supernatant, plus
glucose-6-phosphate, 2 mM; glucose-6-phosphate dehy-
drogenase, 0.14 U/ml; heme, 15 μM; NADPH, 150 μM,
rat liver cytosol as a source of biliverdin reductase,
120 μg/ml; MgCl2, 2 mM, and KH2PO4, 100 mM.
After incubation in darkness for 60 min, the reaction
was stopped by putting the samples on ice. Bilirubin
formation was calculated on the basis of difference
between optical densities obtained at 460 and 530 nm.
The amount of bilirubin (in nanomoles) produced per
hour per milligram protein was defined as one unit of
HO activity.
Differences seen between results of two activity mea-
surements from two different samples but from the same
tissue type may be attributed to HO-1 activity since
other isoforms of the enzyme are of the noninducible,
constitutive form.
Major Investigative Strategies
Experimental Design Strategy I (Part 1 Experiments)
The first major strategy used in the present study was
conducted to find the best dosage and to evaluate the capacity
of α-MSH to mitigate I/R-induced ocular pathologies. This
strategy (Table 1) included the following major features: the
animals were divided randomly into two major treatment
groups, groups I-a and I-b (n=30 in each group). Group I-a
served as a dose–response study group and included five
subgroups: a control group and four treatment groups (n=6
in each subgroup). Twelve hours before induction of ischemia,
vehicle-treated controls were given subcutaneous (s.c.) phys-
iological saline, while the other four groups were administered
s.c. 50, 250, 500, and 1,000 μg/kg α-MSH (Sigma-Aldrich),
respectively.α-MSH used for experiments described here was
prepared as a solution of the hormone in physiological saline.
Group I-b, which was considered to estimate the
effects of α-MSH, included two subgroups (n=15 in
each subgroup). Twelve hours before induction of is-
chemia vehicle-treated controls were given physiologi-
cal saline (s.c.), while the other subgroup was
administered 500 μg/kg α-MSH (s.c.), an effective dose
previously identified in group I-a by electroretinograph-
ic measurements.
Animals in group I-a were subjected to 30 min of ische-
mia in one eye as described above, followed by a 24-h
period of reperfusion and ERG measurements as described
above. Group I-b animals received 90 min of ischemia in
one eye, followed by the same 24-h reperfusion treatment
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that group I-a animals were administered. The basis for
selection of the two aforementioned ischemic time intervals
is based on a previous observation by the authors of the
present study that retinal edema, a focus of study in this
research, fails to develop following only 30 min of ischemia
but develops definitively in rat eyes treated for 90 min
(Szabo et al. 1991). However, a 90-min ischemic period
induces near blindness, making ERG measurements imprac-
tical. Hence, the design strategy for part 1 of the present
study incorporated two major groups of animals segregated
according to the length of the ischemic period prior to
reperfusion.
Bulbi collected from group I-b were divided into
three groups (n=5 in each group), and segregated
according to processing for evaluation of α-MSH influ-
ence on I/R-related pathologies. The first group of
samples was subjected to histological examination
using HE-stained sections and light microscopy; the
second group was osmium-fixed and analyzed by elec-
tron microscopy; and a third group of bulbar samples
was used as source material for a Western blot assay as
described above.
Experimental Design Strategy II (Part 2 Experiments)
Part II experiments were conducted to evaluate the
efficacy of post-ischemic α-MSH-treatment against I/R
injury and also to assess the significance of HO-1 in the
effect of α-MSH. This experimental design strategy
(Table 2.) included the following major features:
Animals (group II; n=20) were divided randomly into
four major treatment cohorts (n=5 in each group), des-
ignated as shown below with drugs administered
according to the indicated timeline.
Control animals were treated intraperitoneally (i.p.) with
vehicle of SnPP (described below) 5, 3, and 1 day before
induction of ischemia, and then with physiological saline
(vehicle of α-MSH) subcutaneously at the outset of post-
ischemic reperfusion.
A second group of animals were treated with vehicle of
SnPP (i.p.) 5, 3, and 1 day before induction of ischemia and
then with 500 μg/kg α-MSH (s.c.) at the outset of
postischemic reperfusion. α-MSH used for experiments de-
scribed here was prepared as a solution of the hormone in
physiological saline.
A third group of animals were treated with 50 μmol/kg
SnPP (i.p.) 5, 3, and 1 day before the induction of ischemia,
and then with 500 μg/kg α-MSH (s.c.) at the outset of post-
ischemic reperfusion. SnPP (Frontier Scientific Inc., Logan,
Utah) is a potent inhibitor of HO-1 (Drummond and Kappas
1981). SnPP was dissolved in 0.1 N sodium hydroxide,
adjusted with HCl to pH 7.4 and diluted with physiological
saline. Each batch of SnPP was prepared within 1 h of use
and protected from light.
A fourth group of animals were treated with 50 μmol/kg
SnPP (i.p.) 5, 3, and 1 day before induction of ischemia, and
Table 2 Design strategy of part II experiments
Group II
Treatment 5, 3, then 1 day before ischemia 0.9 % NaCl solution 0.9 % NaCl solution 50 μmol/kg SnPP 50 μmol/kg SnPP
30-min ischemia on one eye
Treatment at the outset of reperfusion 0.9 % NaCl solution 500 μg/kg α-MSH 500 μg/kg α-MSH 0.9 % NaCl solution
24-h reperfusion
Electroretinography, then
Heme oxygenase activity measurement
Shown here are groups and treatments of animals in the second experimental part
Table 1 Design strategy of part I experiments
A—treatment 12 h before ischemia Group I-a
0.9 % NaCl solution 50 μg/kg 250 μg/kg 500 μg/kg 1,000 μg/kg
30-min ischemia and 24-h reperfusion on one eye
Electroretinography
B—treatment 12 h before ischemia Group I-b
0.9 % NaCl solution 500 μg/kg
90-min ischemia and 24-h reperfusion on one eye
Histology OR Electron microscopy OR Western blotting
Shown here are groups and treatments of animals in the first experimental part
562 J Mol Neurosci (2013) 50:558–570
then with physiological saline (s.c.) at the outset of post-
ischemic reperfusion.
Retinal ischemia was applied in each group for 30 min
followed by 24 h of reperfusion. Then ERG and retinal
tissue HO activity measurement were performed to evaluate
the effect of the abovementioned treatment combinations on
I/R injury.
Statistical Analysis
A one-way analysis of variance with a Tukey posttest was
used for Gaussian data results from the D’Agostino and
Pearson omnibus normality test. Data with nonparametric
distribution was analyzed using the Kruskal–Wallis test
along with the Dunn’s posttest.
In Figs. 2, 6b, and 7, results are represented as
percentages with SEM. SEM is also calculated in per-
centage using the following formula: (SEM/R)*(R%),
where R is the average of individual result values (not
percentage). SEM is standard error of the mean calcu-
lated from the individual result values, and R% is the R
expressed in percentage.
Results
Outcomes of Experimental Design Strategy I
(Part I Experiments)
Electroretinographic Selection of Optimal α-MSH Dosage
The initial objective of work performed in part I of the present
study was to identify an effective dose range of α-MSH using
ERG. Figure 1 shows actual voltage levels and the time course
of ERG spikes observed in part I studies, while percentages of
mean values of all ischemic bwaves relative to control baseline
are shown in Fig. 2. Significant differences between non-I/R
values were not observed (data not shown).
I/R injury as measured by ERG b-wave measurements de-
graded retinal function to 31.64 % of that exhibited by
nonischemic (baseline) eyes of control animals (Fig. 2).
Administration of α-MSH dose responsively improved retinal
function in I/R-injured eyes of animals to a value of 66.18 % of
control baseline—a significant outcome achieved in I/R-injured
eyes of animals treated with a 1,000 μg/kg α-MSH
(p<0.001 vs. control I/R). I/R-mediated retinal damage was
Fig. 1 Electroretinograms (group I-a) of baseline (a) and ischemic/reperfused (b) eyes of vehicle-treated (control) animals and ischemic/reperfused
eyes of rats treated with 50, 250, 500, and 1,000 μg/kg α-MSH (c–f, respectively)
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severe to such an extent that α-MSH treatment could not fully
restore function of the tissue to normal levels. Moreover, dose-
responsive improvement in tissue functional parameters leveled
off at a dosage of 1,000 μg/kg, beyond which it is anticipated
that negligibly more favorable changes would be observed.
The optimal effective dose range identified in the present
experimental setting was observed to be 250–500 μg/kg
of α-MSH. Measureable effects of α-MSH-treatment on the b
waves of ERG were also observed at a dosage as low as
50 μg/kg (35.64 % of control baseline); however, the magni-
tude of improvements was not statistically significant at this
dosage, only at higher doses, such as 250 (48.00 %, p<0.001
vs. control I/R) and 500 μg/kg (64.36 %, p<0.001 vs. control
I/R). Treatment with 1,000 μg/kg mediated a significant pro-
tective effect on retinal function, but since no statistically
significant improvement in outcome was observed between
500 and 1,000 μg/kg (64.36 vs. 66.18 %), it has been con-
cluded that a 500-μg/kg dosage is sufficient and probably
optimal for inhibition of I/R-mediated retinal damage.
Evaluation of the Capacity of α-MSH to Mitigate
I/R-Induced Ocular Pathologies
Histology
As shown in Fig. 3, retinal layers become thickened as a
result of I/R-induced interstitial edema formation, an effect
seen by comparison of Fig. 3a, the nonischemic control
retinal sections (control non-I/R) in which no evidence of
tissue damage may be seen, with Fig. 3b, the I/R-injured
retinal tissue from rats not treated with α-MSH (control
I/R). The effect of 500 μg/kg α-MSH is shown in Fig. 3c,
which demonstrates the ability of the hormone to inhibit the
development of I/R-induced damage, principally retinal ede-
ma and resultant thickening. The relative effects on retinal
thickness of I/R injury and α-MSH treatment are shown in
Fig. 3d. Significant differences between control and treated
non-I/R values were not observed (data not shown).
Electron microscopy
EM ultrastructure of retinal pigment cells and photorecep-
tors revealed no apparent morphological changes in cells in
the outer retinal layers following I/R injury (data not
shown). However, I/R-mediated damage to mitochondria
of inner retinal cells was clearly observed. Figure 4a through
c shows damaged mitochondria in inner retinal cells of I/R-
injured retinal tissue from control animals. These images
demonstrate disintegration of the mitochondria due to for-
mation of interior vacuoles. By contrast, inner retinal cell
mitochondria from I/R-injured retinas taken from animals
treated with 500 μg/kg α-MSH appeared intact with no
vacuolization (Fig. 4d through g). Significant differences
between control and treated non-I/R ultrastructure were not
observed (data not shown).
Western Blot Analysis
Western blot analysis of HO-1 expression in ocular
tissue revealed significantly greater amounts of HO-1
protein in I/R-injured bulbi taken from animals receiv-
ing 500 μg/kg α-MSH treatment than from vehicle-
treated rats (p<0.05). The results of these experiments
are shown in Fig. 5. Significant differences between
control and treated non-I/R values were not observed
(data not shown).
Outcomes of Experimental Design Strategy II (Part II
Experiments)
Experiments conducted under part II of the present study
evaluated the efficacy of post-ischemic treatment with α-
Fig. 2 Effects of α-MSH doses on ERG b waves (group I-a). Shown
here are percentages of mean values of b waves measured in
electroretinogramms of baseline and ischemic/reperfused eyes of vehi-
cle-treated (control) animals and ischemic/reperfused eyes of rats treat-
ed with 50, 250, 500, and 1,000 μg/kg α-MSH with standard error of
the mean (SEM). Percentages were calculated relative to control base-
line values. Horizontal lines indicate comparisons. The significance of
comparisons is indicated as follows: ns not significant; *p<0.05; **p<
0.01; ***p<0.001
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MSH in ameliorating I/R injury. Part II experiments also
assessed the significance of HO-1 in outcomes mediated by
α-MSH. Major strategies for making the aforementioned
determinations included post-ischemic administration of α-
MSH at the onset of reperfusion and treatment of selected
groups of animals with SnPP a potent inhibitor of HO-1
(Drummond and Kappas 1981).
Electroretinography
The outcome of part II ERG studies is shown in Fig. 6.
Figure 6a demonstrates one representative ischemic
ERG spike of each of the four treatment groups with
showing actual voltage levels and time-course of ERG
spikes observed in part II studies. ERG outcomes sug-
gest three major trends with respect to effect of each
treatment on retinal integrity: the data in Fig. 6 show
that relative to waveforms recorded for nonischemic
retinas (Control Baseline), I/R injury, and SnPP-
mediated HO-1 inhibition decreased the amplitude and
altered the waveform characteristics in ways indicative
of degraded retinal tissue function. By contrast α-MSH
treatment shifted retinal responses toward improved
retinal function. Interestingly, administration of SnPP
Fig. 3 Effect of α-MSH on
I/R-induced retinal edema
(group I-b). Sagittal sections of
the rat retina showing the
structure of layers in
nonischemic retinal tissue of
vehicle-treated (control)
animals (a), I/R-injured retinal
tissue from vehicle-treated
(control) rats (b), and I/R-
injured retinal tissue from
animals treated with 500 μg/kg
α-MSH (c). d The effect of α-
MSH on the extent of retinal
edema following I/R injury, in
the inner plexiform layer.
Thickness was measured using
a manual scale on each glass
slides. Mean±SEM;
*p<0.05 vs. control I/R
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together with α-MSH did decrease but did not thor-
oughly abolish this protective effect of α-MSH.
The effects of retinal I/R injury and post-ischemic treat-
ments may be clearly visualized by ERG histogram data
shown in Fig. 6b. Here, it can be seen that mean percentage
of b waves relative to control baseline (i.e., effect of post-
ischemic treatment) was 67.69 % of control baseline values in
animals treated with 500 μg/kg α-MSH (p<0.001 vs. control
I/R). This value is even a little bit higher than what could be
observed in outcomes of the part I experiments (i.e. effect
of pre-ischemic treatment), which was 64.36 % of control
baseline values in animals treated with 500 μg/kg α-MSH
(p<0.001 vs. control I/R; see Fig. 2). Mean percentage of b
waves relative to control baseline measured in I/R-injured
retinas from vehicle-treated rats (Control Ischemia) of sec-
ond experimental studies were 33.44 %. Figures 2 and 6b
allow clear comparison of b wave ratios in I/R-injured
retinas from vehicle-treated vs. α-MSH-treated rats in parts
I vs. II ERG experiments. Percentage of SnPP-treated I/R
retinas were observed to be 19.76 % (p<0.001 vs. control
I/R). Dual-treatment (SnPP+MSH) significantly lowered
the b wave percentages vs. MSH-only treatment (55.77
vs. 67.69 %; p<0.01). However, percentage of SnPP+
MSH-treated I/R retinas proved to be significantly higher
than that of SnPP-only treatment (55.77 vs. 19.76 %; p<0.
001). Significant differences between control and treated
non-I/R values were not observed (data not shown).
Measurement of Heme Oxygenase Activity
The outcome of HO activity measurement in ocular tissue of
rats used for part II experiments is provided in Fig. 7. Tissue
activity of the enzyme was amplified by I/R (119.58 % of
control baseline), and even more by treatment of animals with
500 μg/kg α-MSH (159.42 %). Latter effect was diminished
by combined administration of α-MSH with the HO-1 inhib-
itor SnPP (108.77 %). However, there was a slight difference
between SnPP+MSH- and SnPP-only-treated groups (108.77
Fig. 4 EM studies (group I-b).
a–cMitochondria in I/R-injured
inner retinal cells from rats not
treated with α-MSH. These
images demonstrate
disintegration of the
mitochondria due to formation
of interior vacuoles (arrows).
Mitochondria in I/R-injured
inner retinal cells from animals
treated with 500 μg/kg α-MSH
are shown in (d–g). No
vacuolization is seen here
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and 96.60 %, respectively). Nevertheless, the results of HO-
activity measurements exhibit a variability of such magnitude
as to diminish the statistical validity of the data. Significant
differences between control and treated non-I/R values were
also not observed (data not shown).
Discussion
The experiments conducted in part I of the present investi-
gation examined the capacity of α-MSH to protect against
I/R-induced retinal injury. In these studies, α-MSH was
observed to significantly preserve functions of the eyes
subjected to I/R injury. Evidence for this protective effect
is provided by ERG experiments that demonstrated an α-
MSH dose-dependent increase in I/R-damaged retinal b
wave magnitude (Figs. 1 and 2). These results represent
the first demonstration of α-MSH-mediated protection
against I/R injury to the retina. The aforementioned out-
comes are significant in the context of a February 2013
report describing the capacity of resveratrol, a plant poly-
phenol, to therapeutically increase b wave amplitude and
ameliorate the effects of retinal ischemia induced by high
intraocular pressure through a mechanism that prominently
includes upregulation of HO-1 (Liu et al. 2013). Present
study demonstrate that HO-1 activity, although it is not an
exclusive component of α-MSH-mediated protection of
Fig. 5 Western blot analysis for HO-1 protein expression (group I-b).
The HO-1 content of I/R-injured bulbi is represented in arbitrary units
with SEM in animals not receiving α-MSH (control) and rats treated
with 500 μg/kg α-MSH. *p<0.05
Fig. 6 Effects of SnPP and
post-ischemic α-MSH
treatment on ERG voltage
profiles (a) and ERG b-waves
(b) obtained in part II
experiments (group II). Results
are shown for five groups
including: nonischemic retinas
from vehicle-treated rats
(Control Baseline) and I/R-
injured retinas from vehicle-
(Control Ischemia), α-MSH-
(MSH Ischemia), SnPP+α-
MSH- (SnPP+MSH Ischemia),
and SnPP-treated rats (SnPP
Ischemia). Shown on (a) are
representative ERG spikes;
shown on (b) are mean
percentage values (relative to
control baseline) for b waves
measured in electroretinograms
of the aforementioned groups.
Horizontal lines indicate
comparisons. The significance
of comparisons is indicated as
follows: ns not significant;
*p<0.05; **p<0.01;
***p<0.001
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retinal tissue, increases correlating with α-MSH administra-
tion as shown in Fig. 7.
HO-1 expression in injured tissue is a highly conserved
adaptive response that is observed in many tissues in a very
diverse range of organisms (Haines et al. 2012). Previous
work by the authors to develop therapeutic potential of this
enzyme show that upregulation of HO-1 with an inducer
mediates powerful therapeutic effects in vivo (Bak et al.
2006; Bak et al. 2011), further supporting the potential
clinical application of agents that upregulate HO-1.
The activity of HO-1 is increased in response to awide variety
of stressors, including oxidative and inflammatory insults
(Haines et al. 2012), as well as metabolic and hemodynamic
factors such as high glucose (Mahmoud et al. 2013).
Nevertheless, in most cases, the pathophysiological activation
of HO-1 results only in a transient or marginal increase of HO-1
activity that falls below the threshold necessary to activate down-
stream signaling components of the HO system at levels capable
of achieving significant remission of serious inflammatory pa-
thologies (Mahmoud et al. 2013). Thus, strategies for use of HO-
1 as definitive prophylaxis or treatment for retinopathies and
other diseases are expected to increasingly make use of pharma-
cological agents capable of increasing expression and activity of
the enzyme. Previously, the authors have demonstrated that sour
cherry kernel extract is capable of protecting rat retinas against
I/R injury in vivo through activation of HO-1 (Szabo et al. 2004).
The results ofWestern blot analysis of the present study revealed
significantly increased expression of HO-1 in retinal tissue of
I/R-injured eyes from 500 μg/kg α-MSH treated rats in compar-
ison to expression of the enzyme in I/R-injured eyes from
vehicle-treated animals (Fig. 5). This outcome suggests that
HO-1 may be upregulated by α-MSH in ways that might be
significantly augmented by its concurrent pharmacological in-
duction as a therapeutic strategy. α-MSH-mediated increase of
expression of HO-1 in retinal tissue, is not an unexpected obser-
vation. Moreover, results shown in Fig. 7 of the present study
demonstrate that HO-1 activity correlates with the therapeutic
effect of α-MSH, suggesting that inducers of HO-1 may exhibit
additive and perhaps synergistic therapeutic effects when admin-
istered concurrently with α-MSH.
Histological examination of tissue in the present study
revealed that α-MSH-treated animals exhibited significantly
reduced retinal edema following I/R injury (Fig. 3). This
finding is also potentially significant in the context of the role
of HO-1 in protection against retinal edema. Related studies
demonstrate that resveratrol-induced HO-1 upregulation is
observed to protect against retinal damage (Liu et al. 2013).
These results may contribute to development of novel strate-
gies for alleviation of retinal edema in ocular disorders.
This study also provides EM demonstrations of suppression
of I/R-induced damage to mitochondria of inner retinal cells by
α-MSH at subcellular level (Fig. 4), which is also a novel result.
The experiments conducted in part II of the present
investigation examined the capacity of post-ischemic ad-
ministration of α-MSH to protect against I/R-induced retinal
injury. A corollary objective was to suggest whether non-
HO-1-dependent pathways might also contribute to protec-
tive effects of α-MSH.
The results of the part II ERG studies reveal that the ampli-
tude of waveforms, which is a function of healthy retinal
function, was decreased by I/R injury but, most strikingly,
increased by post-ischemic α-MSH treatment (Fig. 6). At the
same time, eyes from rats treated with the HO-1 inhibitor SnPP
and α-MSH together exhibited reduced ERG waveform
Fig. 7 Relative HO activities in ocular tissue from eyes harvested in part
II experiments (group II). Results are shown for five groups including:
nonischemic retinas from vehicle-treated rats (Control Baseline) and I/R-
injured retinas from vehicle- (Control Ischemia), α-MSH- (MSH
Ischemia), SnPP+α-MSH- (SnPP+MSH Ischemia), and SnPP-treated
rats (SnPP Ischemia). Activity of the enzyme in ocular tissue of an
aforementioned group is shown as percentage of bilirubin production
by a particular group relative to control baseline eye values with SEM
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amplitude. Also, tissue HO-1 activity correlated with wave-
form amplitudes (Fig. 7). Taken together, clear correlation
between α-MSH, mitigation of I/R injury to retinas, and HO-
1 involvement suggest that α-MSH may mediate protection
from I/R injury substantially via an HO-1-dependent pathway.
Results presented here cannot rule out partial involvement of
some other, as-yet unidentified non-HO-1-dependent mecha-
nisms as well. Exploration of this possibility is the focus of
future research by the authors. Avenues of investigation are
suggested by the work by other investigators, showing that α-
MSH has anti-cytokine activity, inhibits proinflammatory pro-
tein expression, decreases fever, and modulates neuroimmune
activity (Macaluso et al. 1994; Delgado et al. 1998).
The present study provides the first demonstration of the
efficacy of α-MSH in protecting against I/R-induced retinal
damage when administered either before or after an ischemic
event. Moreover, the ability of this hormone to protect the retina
following a period of ischemia lends strength to the hypothesis
thatα-MSH expression is a major physiological countermeasure
to a wide range of stressors, developed early in vertebrate evo-
lution and conserved as an important survival trait. The observa-
tion that post-ischemic administration of α-MSH mediates
protective effects in the same range as pre-ischemic treatment is
encouraging from the perspective of its potential therapeutic use
as well.
Results of the present study validate the hypothesis that
α-MSH mitigates the severity of I/R-induced retinal injury
and reinforce evidence for possible involvement of HO-1.
Of particular interest is the capacity of α-MSH to reconsti-
tute the function of retinal tissue when administered follow-
ing a period of ischemia. This finding suggests that α-MSH
may have a very wide range of uses in the prevention of I/R-
mediated pathologies.
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